Guadecitabine, a next-generation DNMT inhibitor with a prolonged effect, has been tested in GBM patients in combination with immunotherapy (with some promising immune effects) (Lofiego et al., 2024), but its role in radiosensitization is yet to be clearly established. This evidence concerns the gene DNMT1 and glioblastoma.